GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (MEX:WST) » Definitions » 3-Year EPS without NRI Growth Rate

West Pharmaceutical Services (MEX:WST) 3-Year EPS without NRI Growth Rate : -7.70% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is West Pharmaceutical Services 3-Year EPS without NRI Growth Rate?

West Pharmaceutical Services's EPS without NRI for the three months ended in Mar. 2025 was MXN29.66.

During the past 12 months, West Pharmaceutical Services's average EPS without NRI Growth Rate was -36.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was -7.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 16.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of West Pharmaceutical Services was 47.70% per year. The lowest was -22.60% per year. And the median was 11.00% per year.


Competitive Comparison of West Pharmaceutical Services's 3-Year EPS without NRI Growth Rate

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


West Pharmaceutical Services's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's 3-Year EPS without NRI Growth Rate falls into.


;
;

West Pharmaceutical Services 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


West Pharmaceutical Services  (MEX:WST) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


West Pharmaceutical Services 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


West Pharmaceutical Services Business Description

Traded in Other Exchanges
Address
530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.